SOPRON

EQS-News: Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business

Retrieved on: 
Wednesday, April 10, 2024
Informal economy, Automation, EUR, Annual, Health, Sale, Acquisition, Food, SIA, Industrial, HARPS, Mining, Bookkeeping

Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.

Key Points: 
  • Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.
  • Earnings development 2023 in detail:
    The continued operations of the Semperit Group recorded revenue of EUR 721.1 million (–7.5%) in the 2023 financial year.
  • Also considering the proceeds from the sale of Examination Operations (medical business), results in EUR 111.5 million (previous year: EUR –2.8 million).
  • Overview of the main financial figures of the financial year 2023:
    Key figures of the Semperit Group, in EUR million

EQS-News: Semperit AG Holding shows significant annual revenue and results growth in the Industrial Sector

Retrieved on: 
Wednesday, March 22, 2023
Pressure, Medicine, Maintenance, HARPS, Tax, Table tennis rubber, Attention, EBIT, Sale, EBITDA, RTÉ Executive Board, Risk, Growth, Industrial sector in Ethiopia, PTE, Film industry, Lithium, Tourism, Pharmaceutical industry, Semperit, EUR, Industrial

CEO Karl Haider comments on the past financial year: “2022 was a very important year for Semperit: we managed to generate significant revenue growth in a volatile business environment.

Key Points: 
  • CEO Karl Haider comments on the past financial year: “2022 was a very important year for Semperit: we managed to generate significant revenue growth in a volatile business environment.
  • With the sale of the Medical segment, we create the opportunity to grow faster and profitably in the Industrial business.
  • The revenue increase of 32.0% to EUR 734.0 million in the Industrial Sector was thus largely responsible for the revenue growth of 29.6% to EUR 779.8 million in the entire continued operations of the Semperit Group.
  • The earnings per share attributable to the shareholders of Semperit AG Holding are therefore EUR –0.27 for 2022 (2021: EUR 11.99).

DGAP-News: Biotest AG: Biotest increases sales by 9% in the first nine months 2021

Retrieved on: 
Thursday, November 11, 2021
Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Achievement, Tax, Plasma, Process performance qualification protocol, PPQ, COVID-19, Next Level, Research, Czech Republic, Board, Company, EBIT, Plasmapheresis, Collection, EAT, Management, Online gambling

The Biotest Group recorded revenues of 371.4 million in the first nine months of the financial year 2021 (same period of the previous year: 341.6 million).

Key Points: 
  • The Biotest Group recorded revenues of 371.4 million in the first nine months of the financial year 2021 (same period of the previous year: 341.6 million).
  • Earnings before interest and taxes (EBIT) for the first nine months of the financial year 2021 amounted to -11.2 million (same period of the previous year: - 7.8 million).
  • This includes expenses for the Biotest Next Level project in the amount of 57.5 million (same period of the previous year: 59.3 million).
  • In total, Biotest had 26 plasma collection centres in Europe at the end of the first nine months of 2021.

DGAP-News: Biotest AG: Biotest increases sales by 10% in the first half of 2021

Retrieved on: 
Thursday, August 12, 2021
Collection, Plasma, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, COVID-19, PPQ, Management, Board, Tax, EAT, Next Level, Data management, Process performance qualification protocol, EBIT, Research, EBT

In the first half of financial year 2021, the Biotest Group recorded a revenue in the amount of 257.8 million (same period of the previous year: 234.8 million).

Key Points: 
  • In the first half of financial year 2021, the Biotest Group recorded a revenue in the amount of 257.8 million (same period of the previous year: 234.8 million).
  • Furthermore, sales of other products, such as Haemoctin(R) and Albumin were also higher compared to the first half-year of 2020.
  • This includes expenses of 38.0 million for the Biotest Next Level project (same period of the previous year: 40.3 million).
  • The Biotest Group's total earnings after taxes (EAT) for the first half of 2021 amounted to -18.2 million (same period of the previous year: -16.7 million).

DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Hungary

Retrieved on: 
Tuesday, July 20, 2021
Anatomy, Software, Branches of biology, Electromagnetism, Budapest, Plasma, Blood plasma, KDE Plasma 5

Biotest received an operating permit for its 11th plasma collection centre in Hungary from the country's national public health authority OTH.

Key Points: 
  • Biotest received an operating permit for its 11th plasma collection centre in Hungary from the country's national public health authority OTH.
  • Thus, the company is further expanding its plasma collection capacity and is safeguarding the plasma supply to future growth.
  • The first plasma collection centre in Budapest was opened in 2009 by Plazmaszolglat Kft., a 100% subsidiary of Biotest AG.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.